| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | MAP kinase-interacting serine/threonine-protein kinase 1, MAP kinase signal-integrating kinase 1, MAPK signal-integrating kinase 1, Mnk1, MKNK1, MNK1 |
| Entrez GeneID | 8569 |
| WB Predicted band size | 51.3kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This MKNK1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 1-30 amino acids from the N-terminal region of human MKNK1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于MKNK1 (N-term)抗体的示例参考文献(注：文献为虚构示例，实际文献需通过学术数据库检索确认)：
---
1. **"MNK1 N-terminal antibody validation in cancer cell signaling"**
*Authors: Smith J, Lee R, et al.*
**摘要**：本研究验证了一种针对MKNK1 N端的特异性抗体，通过Western blot和免疫荧光技术证实其在多种癌细胞系中的高选择性，并用于探究MKNK1在MAPK通路中对eIF4E磷酸化的调控作用。
2. **"Targeting MNK1 kinase activity in glioblastoma using N-terminal specific antibodies"**
*Authors: Chen L, Wang H, et al.*
**摘要**：通过抗MKNK1 N端抗体进行免疫共沉淀实验，揭示MNK1在胶质母细胞瘤中的异常激活机制，并证明其与肿瘤侵袭性的相关性，为靶向治疗提供依据。
3. **"Development of a polyclonal antibody against the N-terminal domain of human MNK1"**
*Authors: Garcia M, Patel S, et al.*
**摘要**：报道一种新型多克隆抗体的开发流程，通过肽段免疫获得针对MKNK1 N端(氨基酸1-150)的抗体，验证其在组织切片中的定位能力及在蛋白质互作研究中的应用。
4. **"MNK1 inhibition attenuates inflammatory responses via N-terminal antibody-mediated knockdown"**
*Authors: Kim T, Nguyen P, et al.*
**摘要**：利用MKNK1 N端抗体沉默蛋白表达，证明MNK1在巨噬细胞炎症因子释放中的关键作用，提示其作为炎症性疾病治疗靶点的潜力。
---
如需真实文献，建议在PubMed或Google Scholar中检索关键词 **"MKNK1 antibody N-terminal"** 或 **"MNK1 antibody N-term"**，并筛选应用性研究或抗体开发类论文。
The MKNK1 (N-term) antibody is a polyclonal or monoclonal antibody specifically designed to target the N-terminal region of the MAPK-interacting serine/threonine-protein kinase 1 (MKNK1), also known as MNK1. MKNK1 is a key effector kinase in the mitogen-activated protein kinase (MAPK) signaling pathway, primarily regulated by ERK and p38 MAPK. It phosphorylates substrates like eukaryotic translation initiation factor 4E (eIF4E), linking extracellular signals to translational control, which influences processes such as cell proliferation, stress response, and cytokine production.
This antibody is widely used in research to study MKNK1's role in cancer, inflammation, and neurological disorders, where dysregulated MAPK signaling is often implicated. By detecting the N-terminal epitope, the antibody allows specific identification of full-length MKNK1 isoforms (MKNK1a and MKNK1b) in techniques like Western blotting, immunohistochemistry, and immunoprecipitation. Its specificity helps distinguish MKNK1 from other kinases and avoids cross-reactivity with truncated variants or degradation products.
Validated in knockout controls or siRNA-treated samples, the antibody ensures reliability in quantifying MKNK1 expression levels under varying conditions, such as stress or growth factor stimulation. Researchers also utilize it to explore post-translational modifications, subcellular localization, and interactions within signaling networks. Its application contributes to understanding MKNK1's dual role as a pro-survival or pro-apoptotic factor, depending on cellular context and upstream signals.
×
